Ekso Bionics Holdings, Inc. is a Nevada corporation that designs, develops and markets exoskeleton products that augment human strength endurance and mobility. The company concentrates its efforts on the healthcare sector where its technology serves individuals with physical disabilities or impairments in both physical rehabilitation and mobility settings. Its core activities include the engineering of wearable robotic exoskeletons for clinical use and the production of…
Ekso Bionics Holdings, Inc. is a Nevada corporation that designs, develops and markets exoskeleton products that augment human strength endurance and mobility. The company concentrates its efforts on the healthcare sector where its technology serves individuals with physical disabilities or impairments in both physical rehabilitation and mobility settings. Its core activities include the engineering of wearable robotic exoskeletons for clinical use and the production of powered orthoses for personal use in home and community environments. Ekso Bionics Holdings, Inc. also provides related services such as extended warranty programs training and device maintenance to support its product lines. The firm continues to pursue business development initiatives that aim to expand its addressable market and increase long term value for shareholders.
The company generates revenue primarily through the sale and subscription of its exoskeleton devices and associated support contracts. In the Enterprise Health market revenue comes from the sale of EksoNR and Ekso Indego Therapy units to rehabilitation hospitals skilled nursing facilities and outpatient clinics often bundled with training installation and optional EksoCare service agreements. In the Personal Health market revenue is derived from the sale of Ekso Indego Personal units to individual users with spinal cord injury and to distributors such as durable medical equipment providers who facilitate Medicare reimbursement. Additional revenue streams include fees for device servicing repair and short term loaner equipment as well as income from training programs delivered online or in person. The firm also markets the EVO upper body exoskeleton to industrial customers seeking ergonomic solutions and distributes the MediBalance Tutor system under an exclusive agreement in the United States. Subscription arrangements for equipment typically span twelve to thirty six months and may involve third party financiers or retained ownership by the company.
The company operates through the following segment.
- Ekso Bionics Holdings, Inc. operates as one operating and reportable segment that encompasses both the Enterprise Health and Personal Health markets. This segment includes the design manufacture and sale of lower limb exoskeletons such as EksoNR Ekso Indego Therapy and Ekso Indego Personal as well as the upper limb Evo exoskeleton and the MediBalance Tutor disturbance treadmill. Revenue within the segment is generated from direct product sales service contracts training and financing arrangements. The segment also conducts research and development efforts to improve existing products and to explore new indications for use across neurological and industrial applications.
Ekso Bionics Holdings, Inc. holds a niche position within the emerging exoskeleton industry where it competes against traditional therapy providers and other manufacturers of robotic and powered mobility devices. In the Enterprise Health arena the company faces competition from conventional physical therapy approaches treadmill based weight support systems and other lower limb exoskeletons that target gait rehabilitation. Its competitive advantages stem from FDA clearances for multiple indications a lightweight modular design and the ability to integrate with clinical workflows to increase therapy dosage and patient engagement. In the Personal Health market the primary competitors are manual and powered wheelchairs as well as a limited number of other powered exoskeletons that have received regulatory clearance for home and community use. The company differentiates itself through proven clinical benefits such as improved bowel and bladder function cardiorespiratory health and reduced spasticity along with a growing reimbursement pathway through Medicare that enhances accessibility for end users.
The company serves a diverse customer base that includes institutional healthcare providers and individual end users. In the Enterprise Health market its customers consist of inpatient rehabilitation facilities long term acute care hospitals skilled nursing centers and outpatient therapy clinics that purchase EksoNR and Ekso Indego Therapy units to augment their rehabilitation programs. These providers range from small independent clinics to large integrated delivery networks that negotiate multi unit purchases. In the Personal Health market the company sells Ekso Indego Personal units to individuals living with spinal cord injury who may obtain coverage through Medicare veteran affairs programs worker compensation or private payment. Distribution partners such as durable medical equipment suppliers and veterans service organizations facilitate these transactions. The firm also supplies the Evo upper body exoskeleton to industrial employers in sectors such as aerospace automotive manufacturing and construction who seek to reduce worker fatigue and improve productivity.